Video
Author(s):
“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.
In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.